Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Niraparib by GSK for Metastatic Melanoma: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Niraparib by GSK for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Niraparib by GSK for Esophageal Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...
Niraparib by GSK for Glioblastoma Multiforme (GBM): Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Niraparib by GSK for Recurrent Malignant Glioma: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Recurrent Malignant Glioma. According to GlobalData, Phase...
Niraparib by Johnson & Johnson for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Niraparib is under clinical development by Johnson & Johnson and currently in Pre-Registration for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Niraparib by GSK for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Niraparib by GSK for Oropharyngeal Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Niraparib by GSK for Laryngeal Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Niraparib by GSK for Hypopharyngeal Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
Niraparib by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Niraparib by GSK for Uterine Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II...
Niraparib by GSK for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
Niraparib by GSK for Gastric Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Niraparib by GSK for Cervical Cancer: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Niraparib by Johnson & Johnson for Prostate Cancer: Likelihood of Approval
Niraparib is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData,...
Niraparib by GSK for Renal Cell Carcinoma: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...